<?xml version="1.0" encoding="UTF-8" ?><dbgapss xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbgapssws.1.0.xsd"><Study uid="27616" whole_study_id="5354" phs="000101" v="5" p="1" createDate="2017-12-18T10:55:15-05:00" completedByGPADate="2018-01-18T18:10:34-05:00" modDate="2019-07-19T13:31:45-05:00" maxParentChildStudyModDate="2019-07-19T13:31:45-05:00" handle="ALS_FirstStage" num_participants="544"><StudyInfo accession="phs000101.v5.p1" parentAccession="phs000101.v5.p1"><BioProject id="PRJNA75709" entrez_id="75709" type="bp_admin_access"/><BioProject id="PRJNA75711" entrez_id="75711" type="bp_data_submission"/><StudyNameReportPage>http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/amyotrophiclateralsclerosis.htm</StudyNameReportPage><StudyNameEntrez>Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data </StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="Yes"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="No"/><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="Yes"/><StudyType21 name="subject_samples" chosen="Yes"/><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>phenotype_data</StudyType><StudyType>genotype_data</StudyType></StudyTypes><Publications><Publication><Unparsed>Schymick JC, Scholz SW, Fung HC, Britton A, Arepalli S, Gibbs JR, Lombardo F, Matarin M, Kasperaviciute D, Hernandez DG, Crews C, Bruijn L, Rothstein J, Mora G, Restagno G, Chi? Singleton A, Hardy J, Traynor BJ. 
Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. 
Lancet Neurol. 2007 Apr; 6(4):322-8. </Unparsed></Publication></Publications><Funding>P01 NS040256-03</Funding></StudyInfo><Authority><ICs><IC id="7" name="NINDS" is_funding_ic="false" is_admin_ic="false" primary="true"/></ICs><Persons><Person nedid="JOHNHARDY" aid="2" auth="eRA" login="JOHNHARDY" fname="John" mname="A." lname="Hardy" email="j.hardy@ucl.ac.uk"><Role>PI</Role><Organization>UNIVERSITY COLLEGE LONDON</Organization></Person><Person nedid="0012211742" aid="1" auth="cit" login="gubitza" fname="Amelie" mname="Katrin" lname="Gubitz" email="ag406h@nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person nedid="0013043239" aid="1" auth="cit" login="pretels" fname="Renate" mname="S" lname="Pretel" email="pretels@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0011559580" aid="1" auth="cit" login="stefanov" fname="Stefan" mname="Alexandrov" lname="Stefanov" email="stefanov@mail.nih.gov"><Role>GENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0010146585" aid="1" auth="cit" login="zhangr" fname="Ran" mname="" lname="Zhang" email="zhangr@mail.nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="false" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><acknowledgement_statement>INSTRUCTIONS:  This study has not provided a suggested acknowledgement statement. However, Approved Users are expected to acknowledge the Submitting Investigator(s) who submitted data from the original study to an NIH-designated data repository, the primary funding organization that supported the Submitting Investigator(s), and the NIH-designated data repository (e.g., dbGaP).  The acknowledgment statement should include the dbGaP accession number to the specific version of the dataset(s) analyzed.</acknowledgement_statement><ic_specific_access_term/><DUC universal_duc="Yes"><File full_url="https://dbgap.ncbi.nlm.nih.gov/aa/docs/Static_DUC_20190419.pdf" filename="Static_DUC_20190419.pdf" content-type="application/pdf"/></DUC><DUC_PDF universal_duc="Yes"><File full_url="https://dbgap.ncbi.nlm.nih.gov/aa/docs/Static_DUC_20190419.pdf" filename="Static_DUC_20190419.pdf" content-type="application/pdf"/></DUC_PDF><GSR_Access gsr_mode="unrest_access_by_timeout" gsr_mode_label="Unrestricted access (institution did not respond within six months)"/><ConsentGroup uid="1171" CGType="cg_class_GRU" title="General Research Use" name="GRU" dac_uid="53" dac_name="NINDS" irb-approval-required="No"><Use-Restriction>Use of the data is limited only by the terms of the model Data Use Certification.

These data will be used only for research purposes. They will not be used to determine the individual identity of any person or their relationship to another person.</Use-Restriction></ConsentGroup><ConsentGroupLinks><ConsentGroupLink cg_uid_from="1171"><StudyTo study_uid="10253" name="dbGaP Collection: Compilation of Individual-Level Genomic Data for General Research Use" accession="phs000688.v1"><ConsentGroupTo uid="1115" name="GRU"/></StudyTo></ConsentGroupLink></ConsentGroupLinks></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study><Study uid="10365" whole_study_id="5354" phs="000101" v="4" p="1" createDate="2014-01-02T14:19:07-05:00" completedByGPADate="2014-03-12T12:27:46-05:00" modDate="2020-09-01T11:06:52-05:00" maxParentChildStudyModDate="2020-09-01T11:06:52-05:00" handle="ALS_FirstStage" num_participants="544"><StudyInfo accession="phs000101.v4.p1" parentAccession="phs000101.v4.p1"><BioProject id="PRJNA75709" entrez_id="75709" type="bp_admin_access"/><BioProject id="PRJNA75711" entrez_id="75711" type="bp_data_submission"/><StudyNameReportPage>http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/amyotrophiclateralsclerosis.htm</StudyNameReportPage><StudyNameEntrez>Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data </StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="Yes"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="No"/><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="Yes"/><StudyType21 name="subject_samples" chosen="Yes"/><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>phenotype_data</StudyType><StudyType>genotype_data</StudyType></StudyTypes><Publications><Publication><Unparsed>Schymick JC, Scholz SW, Fung HC, Britton A, Arepalli S, Gibbs JR, Lombardo F, Matarin M, Kasperaviciute D, Hernandez DG, Crews C, Bruijn L, Rothstein J, Mora G, Restagno G, Chi? Singleton A, Hardy J, Traynor BJ. 
Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. 
Lancet Neurol. 2007 Apr; 6(4):322-8. </Unparsed></Publication></Publications><Funding>P01 NS040256-03</Funding></StudyInfo><Authority><ICs><IC id="7" name="NINDS" is_funding_ic="false" is_admin_ic="false" primary="true"/></ICs><Persons><Person nedid="JOHNHARDY" aid="2" auth="eRA" login="JOHNHARDY" fname="John" mname="A." lname="Hardy" email="j.hardy@ucl.ac.uk"><Role>PI</Role><Organization>UNIVERSITY COLLEGE LONDON</Organization></Person><Person nedid="0012211742" aid="1" auth="cit" login="gubitza" fname="Amelie" mname="Katrin" lname="Gubitz" email="ag406h@nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person nedid="0013043239" aid="1" auth="cit" login="pretels" fname="Renate" mname="S" lname="Pretel" email="pretels@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0011559580" aid="1" auth="cit" login="stefanov" fname="Stefan" mname="Alexandrov" lname="Stefanov" email="stefanov@mail.nih.gov"><Role>GENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0010146585" aid="1" auth="cit" login="zhangr" fname="Ran" mname="" lname="Zhang" email="zhangr@mail.nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="false" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><acknowledgement_statement/><ic_specific_access_term/><DUC><File uri="dbgapssws.cgi?blob_id=17782&amp;file=get&amp;page=file" filename="DUC - GWAS in Amyotrophic Lateral Sclerosis and Neurologically Normal Controls - First Stage Analysis and Public Release of Data.docx" md5="fefebcf95d54663797c770e902f06718" size="36208" modDate="2015-11-13T14:42:51-05:00" content-type="application/vnd.openxmlformats-officedocument.word"/></DUC><DUC_PDF><File uri="dbgapssws.cgi?blob_id=17784&amp;file=get&amp;page=file" filename="DUC - GWAS in Amyotrophic Lateral Sclerosis and Neurologically Normal Controls - First Stage Analysis and Public Release of Data.docx.pdf" md5="6bcd036bfa62336125b98ba15532f999" size="104076" modDate="2015-11-13T14:55:18-05:00" content-type="application/pdf"/></DUC_PDF><ConsentGroup uid="1171" CGType="cg_class_GRU" title="General Research Use" name="GRU" dac_uid="53" dac_name="NINDS" irb-approval-required="No"><Use-Restriction>Use of the data is limited only by the terms of the model Data Use Certification.

These data will be used only for research purposes. They will not be used to determine the individual identity of any person or their relationship to another person.</Use-Restriction></ConsentGroup><ConsentGroupLinks><ConsentGroupLink cg_uid_from="1171"><StudyTo study_uid="10253" name="dbGaP Collection: Compilation of Individual-Level Genomic Data for General Research Use" accession="phs000688.v1"><ConsentGroupTo uid="1115" name="GRU"/></StudyTo></ConsentGroupLink></ConsentGroupLinks></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study><Study uid="6211" whole_study_id="5354" phs="000101" v="3" p="1" createDate="2010-06-03T16:32:14-05:00" modDate="2020-09-01T10:07:20-05:00" maxParentChildStudyModDate="2020-09-01T10:07:20-05:00" handle="ALS_FirstStage" num_participants="544"><StudyInfo accession="phs000101.v3.p1" parentAccession="phs000101.v3.p1"><BioProject id="PRJNA75709" entrez_id="75709" type="bp_admin_access"/><BioProject id="PRJNA75711" entrez_id="75711" type="bp_data_submission"/><StudyNameReportPage>http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/amyotrophiclateralsclerosis.htm</StudyNameReportPage><StudyNameEntrez>Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data </StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="Yes"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="No"/><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="Yes"/><StudyType21 name="subject_samples" chosen="Yes"/><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>phenotype_data</StudyType><StudyType>genotype_data</StudyType></StudyTypes><Description>
&lt;p&gt;The cause of sporadic amyotrophic lateral sclerosis (ALS) is unknown. To identify the genetic factors underlying this fatal  neurodegenerative disease, we performed a series of genome-wide association studies of ALS. These studies are divided into  three distinct stages, each associated with a separate data release. A description of each stage is provided below.&lt;/p&gt;  &lt;p&gt;In the first stage, we genotyped 555,352 SNPs in 276 US cases diagnosed with ALS and 271 US controls. These samples were  obtained from the National Institute of Neurological Disorders and Stroke (NINDS) DNA Repository at Coriell. The 276 US cases  were genotyped on Illumina HumanHap550v1.1 SNP arrays, whereas the 271 US controls were genotyped on both Illumina HumanHap250Sv1.0  and Illumina HumanHap300v1.1 SNP arrays. The genotype data was released in June 2008 under the accession number  &lt;a href="./study.cgi?study_id=phs000101.v1.p1"&gt;phs000101.v1.p1&lt;/a&gt; and was associated with the following publication:  Schymick JC et al. (2007) &lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/17362836" target="_blank"&gt;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&lt;/a&gt;.  &lt;i&gt;Lancet Neurology&lt;/i&gt; 6:322-8.&lt;/p&gt;  &lt;p&gt;In the second stage, we extended our genotyping to a larger cohort to identify risk factors with lower effect size. This  portion of the project used a two-step approach: in step A, 545,066 SNPs were genotyped in 553 individuals with ALS  and 2,338 controls. Of note, this cohort included data from the 276 US cases and 271 US controls that had been previously  released in the first stage, &lt;a href="./study.cgi?study_id=phs000101.v1.p1"&gt;phs000101.v1.p1&lt;/a&gt;. The additional 277 ALS  cases that were newly genotyped in this stage were collected in a population-based manner from the North of Italy and were  genotyped on Illumina HumanHap550v1.1 SNP arrays. In step B, we brought forward the 7,600 most associated SNPs from step A,  and genotyped them in an additional cohort consisting of 2,160 cases and 3,008 controls using an Illumina iSelect custom  designed SNP array. The new data generated from this study was released in May 2010 (&lt;a href="./study.cgi?study_id=phs000101.v2.p1"&gt;phs000101.v2.p1&lt;/a&gt;)  and consisted of 1,456 case samples and 773 control samples for which participants provided consent to make their data  publicly available. We do not have permission to publicly release the genotype data from the rest of the samples. This data  release was associated with the following publication: Chi&amp;#242; A et al. (2009)  &lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/19193627" target="_blank"&gt;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&lt;/a&gt;.  &lt;i&gt;Human Molecular Genetics&lt;/i&gt; 18:1524-32.&lt;/p&gt;  &lt;p&gt;In the third stage, we genotyped 601,273 SNPs in an additional set of 236 Italian ALS cases. Together with the 264 Italian  samples genotyped as part of stage 2, this brought the total number of samples that were whole genome genotyped samples to 504. These additional 236 patients  had been collected in a population-based manner from the Piedmonte region in the North of Italy, and were genotyped using  Illumina Human610Quad.v1 SNP arrays. The rational for this stage of the study arose from a &lt;i&gt;Proceedings of the National Academy of Sciences (PNAS)&lt;/i&gt;   publication by Landers et al. 2009, hypothesizing that genetic variation on chromosome 1q24 in the  vicinity of the KIFAP3 gene was associated with a significant improvement in survival of ALS patients. Our data failed to  replicate this finding suggesting that the original finding may have been a false positive finding. The data generated for  the extra 236 Italian ALS cases used in this study was released in April 2011 (&lt;a href="./study.cgi?study_id=phs000101.v3.p1"&gt;phs000101.v3.p1&lt;/a&gt;). This data release  was associated with the following publication: Traynor BJ et al. (2010)  &lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/20566859" target="_blank"&gt;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&lt;/a&gt;.  PNAS 107:12335-8. Of note, 95 of these 236 samples had also been genotyped on the Illumina iSelect custom designed SNP array used in the    second stage of this study (see README.txt file available through dbGaP Authorized Access for list of the 95 samples).&lt;/p&gt;   &lt;p&gt;This study utilized the &lt;a href="./study.cgi?id=phs000006"&gt;NINDS Repository Motor Neuron Disease/ALS Study&lt;/a&gt;,  and &lt;a href="./study.cgi?id=phs000004"&gt;neurologically normal controls&lt;/a&gt; from the sample population which are banked  in the National Institute of Neurological Disorders and Stroke (NINDS Repository) collection.&lt;/p&gt;
 </Description><StudyHistory>
&lt;p&gt;This study is divided into three stages. The first stage was entitled "Genome-wide genotyping in amyotrophic lateral sclerosis and  neurologically normal controls: first stage analysis and public release of data", and was published in &lt;i&gt;Lancet Neurology&lt;/i&gt; in 2007  (&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/17362836" target="_blank"&gt;Schymick et al., 6(4):322-8&lt;/a&gt;). The data from the first  stage analysis was made available on the dbGAP website (study accession: &lt;a href="./study.cgi?id=phs000101"&gt;phs000101.v1.p1&lt;/a&gt;),  and was used in the second stage (see below).&lt;/p&gt;  &lt;p&gt;The second stage was entitled "A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis" and  was published in &lt;i&gt;Human Molecular Genetics&lt;/i&gt; in 2009  (&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/19193627" target="_blank"&gt;Chi&amp;#242; et al, 18(8):1524-32&lt;/a&gt;). The data from the  second stage analysis was made available on the dbGAP website (study accession: &lt;a href="./study.cgi?id=phs000101"&gt;phs000101.v2.p1&lt;/a&gt;).  This paper utilized data from 2,713 case samples and 5,346 control samples. This release of data includes 1,456 case samples  and 773 control samples for which participants provided consent to make their data publicly available. We do not have permission  to publicly release the genotype data from the rest of the samples.&lt;/p&gt;  &lt;p&gt;The third stage was entitled "Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients"  and was published in &lt;i&gt;Proceedings of the National Academy of Sciences&lt;/i&gt; in 2010  (&lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/20566859" target="_blank"&gt;Traynor et al, 107(27):12335-8&lt;/a&gt;). The data from the third  stage analysis was made available on the dbGAP website (study accession: phs000101.v3.p1). This paper utilized data from 504 case  samples. This release of data includes 500 case samples for which participants provided consent to make their data publicly available.  Of note, 264 of these samples were previously released as part of the Chi&amp;#242; et al paper (see above), and 236 samples have not been  previously released. The 264 previously released samples were genotyped on Illumina HumanHap550v1.1 SNP chips,    whereas the 236 newly released samples were genotyped on Illumina Human610Quadv1 SNP chips. Please note that 95 of the 236    samples for which whole genome data is being released in the third stage had also been genotyped on the Illumina iSelect custom    designed SNP array used in the second stage of this study (see README.txt file available through dbGaP Authorized Access for    list of the 95 samples).&lt;/p&gt;
 </StudyHistory><Attributions><Header title="Principal Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Adriano Chi&#242;</AttrName><Institution>Department of Neuroscience, University of Turin, Turin, Italy</Institution></Header><Header title="Principal Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Gabriella Restagno</AttrName><Institution>Molecular Genetics Unit, Department of Clinical Pathology, A.S.O. O.I.R.M.-S.Anna, Turin, Italy</Institution></Header><Header title="Principal Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Gabriele Mora</AttrName><Institution>Salvatore Maugeri Foundation, Lissone, Italy</Institution></Header><Header title="Principal Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Bryan J. Traynor</AttrName><Institution>Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA and Neurology Department, Johns Hopkins University, Baltimore, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Michael Nalls</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Shiao-Lin Lai</AttrName><Institution>Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>J. Raphael Gibbs</AttrName><Institution>Computational Biology Core, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Jennifer C. Schymick</AttrName><Institution>Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Sampath Arepalli</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Dena Hernandez</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Marcel van der Brug</AttrName><Institution>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA and Department of Neuroscience, The Scripps Research Institute, Jupiter, FL, USA</Institution></Header><Header title="Co-Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Allissa Dillman</AttrName><Institution>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Mark Cookson</AttrName><Institution>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Christina Moglia</AttrName><Institution>Department of Neuroscience, University of Turin, Turin, Italy</Institution></Header><Header title="Co-Investigators - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Andrea Calvo</AttrName><Institution>Department of Neuroscience, University of Turin, Turin, Italy</Institution></Header><Header title="Funding Source - &quot;Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients&quot;"><AttrName>Z01-AG000949-02</AttrName><Institution>The Intramural Research Program of the National Institute on Aging, USA</Institution></Header><Header title="Principal Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Adriano Chi&#242;</AttrName><Institution>Department of Neuroscience, University of Turin, Turin, Italy</Institution></Header><Header title="Principal Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Gabriella Restagno</AttrName><Institution>Molecular Genetics Unit, Department of Clinical Pathology, A.S.O. O.I.R.M.-S.Anna, Turin, Italy</Institution></Header><Header title="Principal Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Andrew Singleton</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Principal Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>John Hardy</AttrName><Institution>Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Principal Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Bryan J. Traynor</AttrName><Institution>Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA and Neurology Department, Johns Hopkins University, Baltimore, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Jennifer C. Schymick</AttrName><Institution>Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Sonja W. Scholz</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Federica Lombardo</AttrName><Institution>Molecular Genetics Unit, Department of Clinical Pathology, A.S.O. O.I.R.M.-S.Anna, Turin, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Shiao-Lin Lai</AttrName><Institution>Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Gabriele Mora</AttrName><Institution>Salvatore Maugeri Foundation, Lissone, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Hon-Chung Fung</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Angela Britton</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Sampath Arepalli</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>J. Raphael Gibbs</AttrName><Institution>Computational Biology Core, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Michael Nalls</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Stephen Berger</AttrName><Institution>Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Lydia Coulter Kwee</AttrName><Institution>Center for Human Genetics, Duke University Medical Center, Durham, NC, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Eugene Z. Oddone</AttrName><Institution>Department of Medicine, Duke University Medical Center, Durham, NC, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Jinhui Ding</AttrName><Institution>Computational Biology Core, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Cynthia Crews</AttrName><Institution>Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Ian Rafferty</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Nicole Washecka</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Dena Hernandez</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Luigi Ferrucci</AttrName><Institution>Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Stefania Bandinelli</AttrName><Institution>Geriatric Unit, Azienda Sanitaria di Firenze, Florence, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Jack Guralnik</AttrName><Institution>Laboratory of Epidemiology, Demography and Biometry, National Institute on Aging, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Fabio Macciardi</AttrName><Institution>Department of Science and Biomedical Technology, University of Milan, Milan, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Federica Torri</AttrName><Institution>Department of Science and Biomedical Technology, University of Milan, Milan, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Sara Lupoli</AttrName><Institution>INSPE, San Raffaele Scientific Institute, Milan, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Stephen J. Chanock</AttrName><Institution>Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Gilles Thomas</AttrName><Institution>Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>David J. Hunter</AttrName><Institution>Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Christian Gieger</AttrName><Institution>Institute of Epidemiology, Helmholtz Zentrum M&#252;nchennchen, German Research Center for Environmental Health, Neuherberg/Munich, Germany</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>H. Erich Wichmann</AttrName><Institution>Institute of Epidemiology, Helmholtz Zentrum M&#252;nchennchen, German Research Center for Environmental Health, Neuherberg/Munich, Germany</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Andrea Calvo</AttrName><Institution>Department of Neuroscience, University of Turin, Turin, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Roberto Mutani</AttrName><Institution>Department of Neuroscience, University of Turin, Turin, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Stefania Battistini</AttrName><Institution>Department of Neuroscience, Neurology Section, University of Siena, Siena, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Fabio Giannini</AttrName><Institution>Department of Neuroscience, Neurology Section, University of Siena, Siena, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Claudia Caponnetto</AttrName><Institution>Department of Neuroscience, Ophthalmology and Genetics, University of Genoa, Genoa, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Giovanni Luigi Mancardi</AttrName><Institution>Department of Neuroscience, Ophthalmology and Genetics, University of Genoa, Genoa, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Vincenzo La Bella</AttrName><Institution>Department of Clinical Neurosciences, University of Palermo, Sicily, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Francesca Valentino</AttrName><Institution>Department of Clinical Neurosciences, University of Palermo, Sicily, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Maria Rosaria Monsurr&#242;</AttrName><Institution>Department of Neurological Sciences, Second University of Naples, Caserta, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Gioacchino Tedeschi</AttrName><Institution>Department of Neurological Sciences, Second University of Naples, Caserta, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Kalliopi Marinou</AttrName><Institution>Salvatore Maugeri Foundation, Lissone, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Mario Sabatelli</AttrName><Institution>Neurological Institute, Catholic University and I.CO.M.M. Association for ALS Research, Rome, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Amelia Conte</AttrName><Institution>Neurological Institute, Catholic University and I.CO.M.M. Association for ALS Research, Rome, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Jessica Mandrioli</AttrName><Institution>Department of Neuroscience, S. Agostino - Estense Hospital and University of Modena, Modena, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Patrizia Sola</AttrName><Institution>Department of Neuroscience, S. Agostino - Estense Hospital and University of Modena, Modena, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Fabrizio Salvi</AttrName><Institution>Department of Neurology, Center for Diagnosis and Cure of Rare Diseases, Bellaria Hospital, Bologna, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Ilaria Bartolomei</AttrName><Institution>Department of Neurology, Center for Diagnosis and Cure of Rare Diseases, Bellaria Hospital, Bologna, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Gabriele Siciliano</AttrName><Institution>Department of Neuroscience, University of Pisa, Pisa, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Cecilia Carlesi</AttrName><Institution>Department of Neuroscience, University of Pisa, Pisa, Italy</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Richard W. Orrell</AttrName><Institution>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Kevin Talbot</AttrName><Institution>Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Zachary Simmons</AttrName><Institution>Department of Neurology, Penn State College of Medicine, Hershey, PA, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>James Connor</AttrName><Institution>Department of Neurosurgery, Penn State College of Medicine, Hershey, PA, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Erik P. Pioro</AttrName><Institution>Department of Neurology, Cleveland Clinic, Cleveland, OH, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Travis Dunkley</AttrName><Institution>Neurogenomics Division, Translational Genomics Institute (TGEN), Phoenix, AZ, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Dietrich A. Stephan</AttrName><Institution>Neurogenomics Division, Translational Genomics Institute (TGEN), Phoenix, AZ, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Dalia Kasperaviciute</AttrName><Institution>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Elizabeth M. Fisher</AttrName><Institution>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Sibylle Jabonka</AttrName><Institution>Institute of Clinical Neurobiology, University of Wuerzburg, Wuerzburg, Germany</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Michael Sendtner</AttrName><Institution>Institute of Clinical Neurobiology, University of Wuerzburg, Wuerzburg, Germany</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Marcus Beck</AttrName><Institution>Institute of Clinical Neurobiology, University of Wuerzburg, Wuerzburg, Germany</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Lucie Bruijn</AttrName><Institution>The ALS Association, Palm Harbor, FL, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Jeffrey Rothstein</AttrName><Institution>Department of Neurology, Johns Hopkins University, Baltimore, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Silke Schmidt</AttrName><Institution>Center for Human Genetics, Duke University Medical Center, Durham, NC, USA</Institution></Header><Header title="Funding Source - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>Z01 AG000949-02</AttrName><Institution>Intramural Research Program of the National Institute on Aging, USA</Institution></Header><Header title="Funding Source - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>2005-10 to FL</AttrName><Institution>Istituto Superiore di Sanit224;, Italy</Institution></Header><Header title="Funding Source - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>ES01324</AttrName><Institution>National Institutes of Health, USA</Institution></Header><Header title="Funding Source - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>CSP #500A</AttrName><Institution>The Department of Veterans Affairs Cooperative Studies Program (CSP), USA</Institution></Header><Header title="Funding Source - &quot;A two-stage genome wide association study of sporadic amyotrophic lateral sclerosis&quot;"><AttrName>CSP #478</AttrName><Institution>The Department of Veterans Affairs Cooperative Studies Program (CSP), USA</Institution></Header><Header title="Principal Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>John Hardy</AttrName><Institution>Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Principal Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>Bryan J. Traynor</AttrName><Institution>SDGE, NIMH, NIH, Bethesda, MD, USA and Neurology Department, Johns Hopkins University, Baltimore, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>Jennifer C. Schymick</AttrName><Institution>Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>Sonja W. Scholz</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>Hon-Chung Fung</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>Angela Britton</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>Sampath Arepalli</AttrName><Institution>Molecular Genetics Unit, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>J. Raphael Gibbs</AttrName><Institution>Computational Biology Core, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>Federica Lombardo</AttrName><Institution>Molecular Genetics Unit, Department of Clinical Pathology, A.S.O. O.I.R.M.-S.Anna, Turin, Italy</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>M. Matarin</AttrName><Institution>Molecular Genetic Unit, NIA, NIH, Bethesda, MD</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>D. Kasperaviciute</AttrName><Institution>Department of Neurodegenerative Disease, Institute of Neurology, Queen Square, London, UK</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>D.G. Hernandez</AttrName><Institution>Molecular Genetic Unit, NIA, NIH, Bethesda, MD</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>C. Crews</AttrName><Institution>Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>L. Bruijn</AttrName><Institution>ALS Association, Palm Harbor, FL</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>J. Rothstein</AttrName><Institution>Neurology Department, Johns Hopkins University, Baltimore, MD</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>G. Mora</AttrName><Institution>Division of Neurorehabilitation, Istituto Scientifico di Pavia, Italy</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>G. Restagno</AttrName><Institution>Department of Clinical Pathology, ASO OIRM-S Anna, Turin, Italy</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>Adriano Chi&#242;</AttrName><Institution>Department of Neuroscience, University of Turin, Turin, Italy</Institution></Header><Header title="Co-Investigators - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>Andrew Singleton</AttrName><Institution>Molecular Genetic Unit, NIA, NIH, Bethesda, MD</Institution></Header><Header title="NINDS Repository Project Officer - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>Katrina A. Gwinn</AttrName><Institution>National Institute for Neurological Disorders and Stroke, NIH, Bethesda, MD, USA</Institution></Header><Header title="NINDS Repository Principal Investigator - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>Roderick A. Corriveau</AttrName><Institution>Coriell Institute for Medical Research, Camden, NJ, USA</Institution></Header><Header title="Clinical Investigators, ALSRG - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>H. Mitsumoto</AttrName><Institution>Eleanor and Lou Gehrig MDA/ALS Research Center, Columbia University, New York, NY, USA</Institution></Header><Header title="Clinical Investigators, ALSRG - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>R.H. Brown</AttrName><Institution>Massachusetts General Hospital, Charlestown, MA, USA</Institution></Header><Header title="Clinical Investigators, ALSRG - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>M. Cudkowicz</AttrName><Institution>Massachusetts General Hospital, Charlestown, MA, USA</Institution></Header><Header title="Clinical Investigators, ALSRG - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>P.H. Gordon</AttrName><Institution>Eleanor and Lou Gehrig MDA/ALS Research Center, Columbia University, New York, NY, USA</Institution></Header><Header title="Clinical Investigators, ALSRG - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>E.J. Kasarkis</AttrName><Institution>University of Kentucky, Lexington, KY, USA</Institution></Header><Header title="Clinical Investigators, ALSRG - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>P. Kaufmann</AttrName><Institution>Eleanor and Lou Gehrig MDA/ALS Research Center, Columbia University, New York, NY, USA</Institution></Header><Header title="Clinical Investigators, ALSRG - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>R. Miller</AttrName><Institution>California Pacific Medical Center, San Francisco, CA, USA</Institution></Header><Header title="Clinical Investigators, ALSRG - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>E. Sorenson</AttrName><Institution>Mayo Medical Center, Rochester, MN, USA</Institution></Header><Header title="Clinical Investigators, ALSRG - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>R. Tandan</AttrName><Institution>University of Vermont, Burlington, VT, USA</Institution></Header><Header title="The ALSRG - &quot;Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data&quot;"><AttrName>Various members, Academic Neurologists</AttrName><Institution>See Kaufmann P, Misumoto H (2006) ALS Research Group (ALSRG): Second meeting, a summary report. Amyotrophic Lateral Sclerosis 7: 252-255.</Institution></Header></Attributions><StudyURLs><Url name="NINDS Amyotrophic Lateral Sclerosis" url="http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/amyotrophiclateralsclerosis.htm"/><Url name="NINDS Repository at Coriell Motor Neuron Diseases Resources" url="http://ccr.coriell.org/Sections/Collections/NINDS/?SsId=10"/></StudyURLs><Publications><Publication><Pubmed pmid="19193627"/></Publication><Publication><Pubmed pmid="17362836"/></Publication><Publication><Pubmed pmid="20566859"/></Publication><Publication><Unparsed>Schymick JC, Scholz SW, Fung HC, Britton A, Arepalli S, Gibbs JR, Lombardo F, Matarin M, Kasperaviciute D, Hernandez DG, Crews C, Bruijn L, Rothstein J, Mora G, Restagno G, Chi? Singleton A, Hardy J, Traynor BJ. 
Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. 
Lancet Neurol. 2007 Apr; 6(4):322-8. </Unparsed></Publication></Publications><Funding>P01 NS040256-03</Funding></StudyInfo><Authority><ICs><IC id="7" name="NINDS" is_funding_ic="false" is_admin_ic="false" primary="true"/></ICs><Persons><Person nedid="JOHNHARDY" aid="2" auth="eRA" login="JOHNHARDY" fname="John" mname="A." lname="Hardy" email="j.hardy@ucl.ac.uk"><Role>PI</Role><Organization>UNIVERSITY COLLEGE LONDON</Organization></Person><Person nedid="0012211742" aid="1" auth="cit" login="gubitza" fname="Amelie" mname="Katrin" lname="Gubitz" email="ag406h@nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person nedid="0013043239" aid="1" auth="cit" login="pretels" fname="Renate" mname="S" lname="Pretel" email="pretels@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0011559580" aid="1" auth="cit" login="stefanov" fname="Stefan" mname="Alexandrov" lname="Stefanov" email="stefanov@mail.nih.gov"><Role>GENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0010146585" aid="1" auth="cit" login="zhangr" fname="Ran" mname="" lname="Zhang" email="zhangr@mail.nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><DUC><File uri="dbgapssws.cgi?blob_id=6156&amp;file=get&amp;page=file" filename="ALS_GWAS_Hardy_NINDSDUC_rev012110_clean[1].docx" md5="33d8e653b0ed1f0c706a3250c28e0984" size="33911" modDate="2010-04-26T17:22:22-05:00" content-type="application/vnd.openxmlformats-officedocument.word"/></DUC><DUC_PDF><File uri="dbgapssws.cgi?blob_id=16570&amp;file=get&amp;page=file" filename="ALS_GWAS_Hardy_NINDSDUC_rev012110_clean[1].docx.pdf" md5="1e10f8c6345e03d8c7e04747012ae0d3" size="108880" modDate="2015-08-31T16:01:40-05:00" content-type="application/pdf"/></DUC_PDF><ConsentGroup uid="194" CGType="cg_class_other" title="General research use " name="GRU" dac_uid="53" dac_name="NINDS" irb-approval-required="No"><Use-Restriction>These data will be used only for research purposes. They will not be used to determine the individual identity of any person or their relationship to another person.</Use-Restriction></ConsentGroup></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study><Study uid="5826" whole_study_id="5354" phs="000101" v="2" p="1" createDate="2009-12-30T12:10:08-05:00" modDate="2020-09-01T11:20:24-05:00" maxParentChildStudyModDate="2020-09-01T11:20:24-05:00" handle="ALS_FirstStage" num_participants="544"><StudyInfo accession="phs000101.v2.p1" parentAccession="phs000101.v2.p1"><StudyNameReportPage>http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/amyotrophiclateralsclerosis.htm</StudyNameReportPage><StudyNameEntrez>Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data </StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="No"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="No"/><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="No"/><StudyType21 name="subject_samples" chosen="No"/><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><Description>Background
The cause of sporadic ALS is currently unknown. Despite evidence for a role for genetics, no common genetic variants have been unequivocally linked to sporadic ALS. We sought to identify genetic variants associated with an increased or decreased risk for developing ALS in a cohort of American sporadic cases. 

Methods
We undertook a genome-wide association study using publicly available samples from 276 patients with sporadic ALS and 271 neurologically normal controls. 555 352 unique SNPs were assayed in each sample using the Illumina Infinium II HumanHap550 SNP chip. 

Findings
More than 300 million genotypes were produced in 547 participants. These raw genotype data are freely available on the internet and represent the first publicly accessible SNP data for ALS cases. 34 SNPs with a p value less than 0.0001 (two degrees of freedom) were found, although none of these reached significance after Bonferroni correction. 

Interpretation
We generated publicly available genotype data for sporadic ALS patients and controls. No single locus was definitively associated with increased risk of developing disease, although potentially associated candidate SNPs were identified. 

Reprinted from Lancet Neurology, volume 6, Schymick JC, Scholz SW, Fung HC, et al. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data, 322-8, 2007, with permission from Elsevier. 

This study utilized the NINDS Repository Motor Neuron Disease/ALS Study, and neurologically normal controls from the sample population which are banked in the National Institute of Neurological Disorders and Stroke (NINDS Repository) collection for a first stage whole genome analysis.

NINDS Amyotrophic Lateral Sclerosis 

NINDS Repository at Coriell Motor Neuron Diseases Resources 
</Description><StudyHistory>The study is a collaboration between the Intramural programs of National Institute of Mental Health (Dr. Traynor), Laboratory of Neurogenetics, National Institute on Aging (NIA, Drs. Singleton, Hardy, and other authors), and the extramural National Institutes of Neurological Disorders and Stroke sponsorship of the NINDS Repository (NINDS, including the Repository, Drs. Gwinn and Corriveau) and of the project in the intramural programs cited above. Additional collaborators are affiliated with international programs as listed adjacent to their names in the attribution sections, below. Furthermore, a majority of the samples banked in the NINDS repository (cases and controls) were collected via the ALS Research Group (ALSRG) under NOT-NS-03-016. Investigators who had been collecting and banking samples as a part of the overall NINDS-funded effort in ALS gene discovery prior to the NOT-NS-03-016 initiative also have contributed to this effort (JH,AS,BT). 
</StudyHistory><Diseases><Disease diseaseName="Amyotrophic Lateral Sclerosis "/></Diseases><Publications><Publication><Unparsed>Schymick JC, Scholz SW, Fung HC, Britton A, Arepalli S, Gibbs JR, Lombardo F, Matarin M, Kasperaviciute D, Hernandez DG, Crews C, Bruijn L, Rothstein J, Mora G, Restagno G, Chi? Singleton A, Hardy J, Traynor BJ. 
Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. 
Lancet Neurol. 2007 Apr; 6(4):322-8. </Unparsed></Publication></Publications><Funding>P01 NS040256-03</Funding></StudyInfo><Authority><ICs><IC id="7" name="NINDS" is_funding_ic="false" is_admin_ic="false" primary="true"/></ICs><Persons><Person nedid="JOHNHARDY" aid="2" auth="eRA" login="JOHNHARDY" fname="John" mname="A." lname="Hardy" email="j.hardy@ucl.ac.uk"><Role>PI</Role><Organization>UNIVERSITY COLLEGE LONDON</Organization></Person><Person nedid="0010150700" aid="1" auth="cit" login="tagled" fname="Danilo" mname="A" lname="Tagle" email="tagled@mail.nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person nedid="0013043239" aid="1" auth="cit" login="pretels" fname="Renate" mname="S" lname="Pretel" email="pretels@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0010787587" aid="1" auth="cit" login="gwinnk" fname="Katrina" mname="Ann" lname="Gwinn-Hardy" email="gwinnk@ninds.nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><DUC><File uri="dbgapssws.cgi?blob_id=6156&amp;file=get&amp;page=file" filename="ALS_GWAS_Hardy_NINDSDUC_rev012110_clean[1].docx" md5="33d8e653b0ed1f0c706a3250c28e0984" size="33911" modDate="2010-04-26T17:22:22-05:00" content-type="application/vnd.openxmlformats-officedocument.word"/></DUC><ConsentGroup uid="128" CGType="cg_class_other" title="General research use " name="GRU" dac_uid="53" dac_name="NINDS" irb-approval-required="No"><Use-Restriction>These data will be used only for research purposes. They will not be used to determine the individual identity of any person or their relationship to another person.</Use-Restriction></ConsentGroup></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study><Study uid="5354" whole_study_id="5354" phs="000101" v="1" p="1" createDate="2008-09-23T12:03:00-05:00" modDate="2020-09-01T10:17:58-05:00" maxParentChildStudyModDate="2020-09-01T10:17:58-05:00" handle="ALS_FirstStage" num_participants="544"><StudyInfo accession="phs000101.v1.p1" parentAccession="phs000101.v1.p1"><StudyNameReportPage>http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/amyotrophiclateralsclerosis.htm</StudyNameReportPage><StudyNameEntrez>Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data </StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="No"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="No"/><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="No"/><StudyType21 name="subject_samples" chosen="No"/><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><Description>Background
The cause of sporadic ALS is currently unknown. Despite evidence for a role for genetics, no common genetic variants have been unequivocally linked to sporadic ALS. We sought to identify genetic variants associated with an increased or decreased risk for developing ALS in a cohort of American sporadic cases. 

Methods
We undertook a genome-wide association study using publicly available samples from 276 patients with sporadic ALS and 271 neurologically normal controls. 555 352 unique SNPs were assayed in each sample using the Illumina Infinium II HumanHap550 SNP chip. 

Findings
More than 300 million genotypes were produced in 547 participants. These raw genotype data are freely available on the internet and represent the first publicly accessible SNP data for ALS cases. 34 SNPs with a p value less than 0.0001 (two degrees of freedom) were found, although none of these reached significance after Bonferroni correction. 

Interpretation
We generated publicly available genotype data for sporadic ALS patients and controls. No single locus was definitively associated with increased risk of developing disease, although potentially associated candidate SNPs were identified. 

Reprinted from Lancet Neurology, volume 6, Schymick JC, Scholz SW, Fung HC, et al. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data, 322-8, 2007, with permission from Elsevier. 

This study utilized the NINDS Repository Motor Neuron Disease/ALS Study, and neurologically normal controls from the sample population which are banked in the National Institute of Neurological Disorders and Stroke (NINDS Repository) collection for a first stage whole genome analysis.

NINDS Amyotrophic Lateral Sclerosis 

NINDS Repository at Coriell Motor Neuron Diseases Resources 
</Description><StudyHistory>The study is a collaboration between the Intramural programs of National Institute of Mental Health (Dr. Traynor), Laboratory of Neurogenetics, National Institute on Aging (NIA, Drs. Singleton, Hardy, and other authors), and the extramural National Institutes of Neurological Disorders and Stroke sponsorship of the NINDS Repository (NINDS, including the Repository, Drs. Gwinn and Corriveau) and of the project in the intramural programs cited above. Additional collaborators are affiliated with international programs as listed adjacent to their names in the attribution sections, below. Furthermore, a majority of the samples banked in the NINDS repository (cases and controls) were collected via the ALS Research Group (ALSRG) under NOT-NS-03-016. Investigators who had been collecting and banking samples as a part of the overall NINDS-funded effort in ALS gene discovery prior to the NOT-NS-03-016 initiative also have contributed to this effort (JH,AS,BT). 
</StudyHistory><Diseases><Disease diseaseName="Amyotrophic Lateral Sclerosis "/></Diseases><Publications><Publication><Unparsed>Schymick JC, Scholz SW, Fung HC, Britton A, Arepalli S, Gibbs JR, Lombardo F, Matarin M, Kasperaviciute D, Hernandez DG, Crews C, Bruijn L, Rothstein J, Mora G, Restagno G, Chi? Singleton A, Hardy J, Traynor BJ. 
Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. 
Lancet Neurol. 2007 Apr; 6(4):322-8. </Unparsed></Publication></Publications><Funding>P01 NS040256-03</Funding></StudyInfo><Authority><ICs><IC id="7" name="NINDS" is_funding_ic="false" is_admin_ic="false" primary="true"/></ICs><Persons><Person nedid="JOHNHARDY" aid="2" auth="eRA" login="JOHNHARDY" fname="John" mname="A." lname="Hardy" email="j.hardy@ucl.ac.uk"><Role>PI</Role><Organization>UNIVERSITY COLLEGE LONDON</Organization></Person><Person nedid="0010150700" aid="1" auth="cit" login="tagled" fname="Danilo" mname="A" lname="Tagle" email="tagled@mail.nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person nedid="0013043239" aid="1" auth="cit" login="pretels" fname="Renate" mname="S" lname="Pretel" email="pretels@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><DUC><File uri="dbgapssws.cgi?blob_id=5356&amp;file=get&amp;page=file" filename="C:\Documents and Settings\feolo\My Documents\dbGaP\SubmissionSystem\NINDS_stroke_v1_DUC.pdf" size="63816" modDate="2008-09-23T12:06:05-05:00" content-type="application/pdf"/></DUC><DUC_PDF><File uri="dbgapssws.cgi?blob_id=5356&amp;file=get&amp;page=file" filename="C:\Documents and Settings\feolo\My Documents\dbGaP\SubmissionSystem\NINDS_stroke_v1_DUC.pdf" size="63816" modDate="2008-09-23T12:06:05-05:00" content-type="application/pdf"/></DUC_PDF><ConsentGroup uid="5" CGType="cg_class_other" title="General research use " name="GRU" dac_uid="53" dac_name="NINDS" irb-approval-required="No"><Use-Restriction>These data will be used only for research purposes. They will not be used to determine the individual identity of any person or their relationship to another person.</Use-Restriction></ConsentGroup></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study></dbgapss>